FDA Okays First-in-Class Treatment for Obstructive HCM

Mavacamten is a first-in-class allosteric and reversible inhibitor selective for cardiac my-osin that targets the underlying pathophysiology of obstructive hypertrophic cardiomyo-pathy.
FDA Approvals

source https://www.medscape.com/viewarticle/972945?src=rss